Aileron Therapeutics

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. Based in Austin, Texas and incorporated in 2012, the company is dedicated to addressing severe complications associated with pneumonia, such as loculated pleural effusion, where fluid accumulation and scar tissue hinder drainage. Its lead product, LTI-01, is an injectable fibrinolytic drug designed to safely clear fibrinous scar tissue, facilitating the drainage of pleural fluid without the need for surgery. In addition to LTI-01, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis, aiming to enhance treatment pathways for these serious conditions. Through its targeted approach, Lung Therapeutics seeks to improve clinical outcomes for patients with life-threatening lung diseases.